Back

Three months of weekly rifapentine and isoniazid versus four months of rifampicin for tuberculosis infection: a randomised controlled trial

2025-08-21 respiratory medicine Title + abstract only
View on medRxiv
Show abstract

BackgroundTreatment of tuberculosis infection (TBI) is a cornerstone of the WHO End TB Strategy. Two widely recommended short-course regimens--weekly isoniazid plus rifapentine for 12 weeks (3HP) and daily rifampicin for 16 weeks (4RIF)--have not been directly compared in a randomised trial. This study aimed to compare treatment completion between 3HP and 4RIF among individuals with TBI. MethodsWe conducted a multicentre, open-label, parallel-group, randomised controlled trial at seven tubercul...

Predicted journal destinations